ReviewBiomarkers in medicine2010
Biomarkers in systemic sclerosis.
Review in Biomarkers in medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 87 citations in OpenAlex.
- Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.Blood · 2011Trial
- Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics.Arthritis research & therapy · 2025Article
- Comparative transcriptomic analysis validates iPSC derived in-vitro progressive fibrosis model as a screening tool for drug discovery and development in systemic sclerosis.Scientific reports · 2024Article
- Serum biomarkers in patients with hand-arm vibration injury and in controls.Scientific reports · 2024Article
- Polyneuropathy in systemic sclerosis: exploring the causes and biomarkers.Frontiers in medicine · 2024Article
- Review
- Perspective to precision medicine in scleroderma.Frontiers in immunology · 2023Article
- The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.International journal of molecular sciences · 2022Article
- Article
- An in vivo confocal microscopy study of corneal changes in patients with systemic sclerosis.Scientific reports · 2021Article
- Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.Scientific reports · 2021Article
- Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases.Frontiers in pharmacology · 2021Article
- Translational optical coherence elastography for assessment of systemic sclerosis.Journal of biophotonics · 2019Article
- Existing and novel biomarkers for precision medicine in systemic sclerosis.Nature reviews. Rheumatology · 2018Review
- Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.BioMed research international · 2018Observational
- Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis.Nature communications · 2017Article
- Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis.Molecular therapy. Nucleic acids · 2017Article
- Rapid, noninvasive quantitation of skin disease in systemic sclerosis using optical coherence elastography.Journal of biomedical optics · 2016Article
- Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction.Clinical rheumatology · 2015Article
- Personalized medicine in systemic sclerosis: facts and promises.Current rheumatology reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic sclerosis is an autoimmune inflammatory disorder of unknown etiologycharacterized b y pronounced fibroproliferative alterations in the microvasculature, and frequent cellular and humoral immunity abnormalities, culminating in a severe and often progressive fibrotic process. Numerous biomarkers reflecting the three main pathogenetic mechanisms in systemic sclerosis have been described; however, aside from several disease-specific autoantibodies, other biomarkers have not been thoroughly validated and require further study. Thus, there is an unmet need for validated biomarkers for diagnosis, disease classification, and evaluation of organ involvement and therapeutic response in systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.